WooGene B&G Co. Ltd (018620) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

Based on the latest financial reports, WooGene B&G Co. Ltd (018620) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩987.57 Million ≈ $669.26K USD) by net assets (₩66.90 Billion ≈ $45.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

WooGene B&G Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how WooGene B&G Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 018620 total debt and obligations for a breakdown of total debt and financial obligations.

WooGene B&G Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of WooGene B&G Co. Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
High Coast Distillery AB
ST:HIGHCO-B
0.005x
Euro Manganese Inc
AU:EMN
3.412x
Trematon Capital Investments
JSE:TMT
0.068x
Thanasiri Group Public Company Limited
BK:THANA
0.024x
Winamp Group SA
PA:ALPET
N/A
Bal Pharma Limited
NSE:BALPHARMA
0.129x
IntegraFin Holdings plc
LSE:IHP
0.599x
Integritas Viager SA
PA:MLVIE
N/A

Annual Cash Flow Conversion Efficiency for WooGene B&G Co. Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of WooGene B&G Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see WooGene B&G Co. Ltd market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩27.79 Billion
≈ $18.83 Million
₩6.78 Billion
≈ $4.60 Million
0.244x +540.75%
2023-12-31 ₩72.33 Billion
≈ $49.02 Million
₩2.76 Billion
≈ $1.87 Million
0.038x -47.68%
2022-12-31 ₩35.32 Billion
≈ $23.93 Million
₩2.57 Billion
≈ $1.74 Million
0.073x -44.60%
2021-12-31 ₩31.14 Billion
≈ $21.11 Million
₩4.09 Billion
≈ $2.77 Million
0.131x +58.90%
2020-12-31 ₩29.85 Billion
≈ $20.23 Million
₩2.47 Billion
≈ $1.67 Million
0.083x +221.95%
2019-12-31 ₩27.27 Billion
≈ $18.48 Million
₩-1.85 Billion
≈ $-1.25 Million
-0.068x +51.68%
2018-12-31 ₩26.51 Billion
≈ $17.97 Million
₩-3.72 Billion
≈ $-2.52 Million
-0.140x -110.00%
2017-12-31 ₩23.04 Billion
≈ $15.61 Million
₩-1.54 Billion
≈ $-1.04 Million
-0.067x -151.96%
2016-12-31 ₩22.14 Billion
≈ $15.00 Million
₩2.85 Billion
≈ $1.93 Million
0.129x +279.51%
2015-12-31 ₩21.90 Billion
≈ $14.84 Million
₩-1.57 Billion
≈ $-1.06 Million
-0.072x -199.97%
2014-12-31 ₩20.67 Billion
≈ $14.01 Million
₩1.48 Billion
≈ $1.00 Million
0.072x -36.08%
2012-12-31 ₩18.56 Billion
≈ $12.58 Million
₩2.08 Billion
≈ $1.41 Million
0.112x +157.29%
2011-12-31 ₩17.74 Billion
≈ $12.02 Million
₩773.08 Million
≈ $523.90K
0.044x --

About WooGene B&G Co. Ltd

KQ:018620 Korea Pharmaceuticals
Market Cap
$13.13 Million
₩19.37 Billion KRW
Market Cap Rank
#26201 Global
#1952 in Korea
Share Price
₩746.00
Change (1 day)
+4.78%
52-Week Range
₩670.00 - ₩1004.00
All Time High
₩6913.04
About

WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. T… Read more